Date: Thursday, October 13
Time: 13:30 – 14:45
Session Hall 3
If not now, then when? The importance of early intervention for obesity
Following this symposium, learners will be more confident:
• Implementing evidence-based treatment options to address weight early in youth
• Tailoring obesity management strategies in children and adolescents according to guidelines
Programme and Speakers:
Welcome and introduction
Rita Nawar, (Chair)
Importance of early obesity intervention to improve outcomes for youth
Rita Nawar
Overcoming barriers and challenges in treatment of childhood obesity
Jason Halford
Completing the obesity treatment jigsaw
Aaron Kelly
Discussion
Date: Thursday, October 13
Time: 13:30 – 14:45
Session Hall 2
Automated Insulin Delivery Systems as therapy of choice for the young with type 1 diabetes
Program and Speakers:
Introduction
Prof. Tadej Battelino (Chair)
Glycemic outcomes and safety with MiniMed™ 780G system in children with type 1 diabetes aged 2-6 years
Dr. Anna-Kaisa Tuomaala
From MDI to MiniMed™ 780G in challenging youth with type 1 diabetes in a real-world setting
Prof. Ben Wheeler
Meal management simplification using the MiniMed™ 780G system in adolescents with type 1 diabetes
Prof. Goran Petrovski
Longitudinal real-world evidence in the young MiniMed™ 780G system users
Prof. Ohad Cohen
Questions & Answers
Dr. Jen McVean (Chair)
Date: Friday, October 14
Time: 07:00- 08:00
Session Hall 4
Program & Speakers:
Introduction on Prevalence of Adolescents Obesity in the UAE
Dr Asmaa Deeb
New Hope in management of Adolescents with Obesity
Dr Andrea Scaramuzza
Q&A
Both
Date: Friday, October 14
Time: 12:00-13:15
Session Hall 2
Elevating the Standard of Care in Glucose Monitoring with Dexcom CGM
Program and Speakers:
Optimizing Technology in T1D: What You Need to Know for Your Pediatric Patients on the Fast Track to Automated Insulin Delivery
Anita Swamy, MD; Associate Clinician, Lurie Children’s, Assistant Professor of Pediatrics, Northwestern University, Feinberg School of Medicine
Accuracy, Performance, and Clinical Benefit for T1D Pediatric Patients Using Dexcom G7
Paul Wadwa, MD; Professor of Pediatrics, Barbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine
Dexcom G7: Onboarding and Early Clinical Experience with Dexcom G7
Zoe Cholewa, Leeds Metropolitan University
Date: Friday, October 14
Time: 12:00-13:15
Workshop Room
Type 1 Diabetes: Importance of Early Identification and Preservation of Beta Cell Function
Screening studies for islet autoantibodies have demonstrated reduced DKA and hospitalization at onset of clinical disease and improved long-term glycemic control. Beta cell preservation has been shown to lower rates of microvascular disease, such as retinopathy and albuminuria, and hypoglycemia. Intervention in early-stage T1D may preserve beta cell function. Teplizumab, an FcR-nonbinding humanized CD3 monoclonal antibody, was studied for the delay of clinical T1D. The results of that study will be discussed. The safety and efficacy of teplizumab have not been established.
Professor Thomas Danne, MD
Professor Michel Polak, MD, PhD
Date: Saturday, October 15
Time: 07:45 – 08:45
Session Hall 4
Continued Success with Control-IQ Technology in Pediatric Populations
Marc Breton, PhD
Amélie Poidvin, MD
Laurel Messer, PhD, RN
Date: Saturday, October 15
Time: 07:45 – 08:45
Session Hall 3
Moving with the times: Exercise, CGM and glycemic control in Type 1 diabetes
Program & Speakers:
Welcome and introduction
Chair: Asma Deeb
Exploring the evidence: Clinical outcomes for young people with Type 1 diabetes
Thomas Danne
Setting the scene: Exercise and glycemic management for people with Type 1 diabetes
Asma Deeb
Management through metrics: Using CGM to support optimal diabetes control in Type 1 diabetes
Tadej Battelino
Q&A
All faculty
Closing summary
Asma Deeb
Date: Saturday, October 15
Time: 13:15 – 14:30
Session Hall 2
Use of Advanced Technologies for the Treatment of T1 Diabetes:
Real World Experience with CSII and Future Innovation with AID
• Regional Perspectives on Diabetes Management: What are the obstacles to
improving care?
• Improving Glycaemic Outcomes with the Omnipod DASH® System: Real world
Experience
• Adoption to Advanced Technologies in Type 1 Diabetes
Speakers to be announced.
Date: Saturday, October 15
Time: 13:15 – 14:30
Workshop Room
Treating the young with the MiniMed™ 780G Advanced Hybdrid Closed Loop System: Expert Insights
Program & Speakers:
Introduction
Chair: Dr. Jen McVean
Practical insights into the use of MiniMed™ 780G system in the younger population
Dr. Henk-Jan Aanstoot
Open Discussion
All
Date: Saturday, October 15
Time: 17:45 – 19:15
Workshop Room
How to Create More Moments that Count
Quick and Easy Tools to Interpret and Adjust the t:slim X2 with Control-IQ Technology
Laurel Messer, PhD, RN, CDCES
